Qurient

Innovation for
Unmet
Medical
Needs

Global Leader
of Network
R&D

Clinical & non-clinical
pipeline with
Global
standard

Notice

2025-05-12	큐리언트 항암제 Q901, 국제일반명 등재…'모카시클립'으로 확정
2025-04-29	큐리언트, AACR에서 아드릭세티닙 임상 1상 최종결과 발표
2025-04-01	큐리언트, 텔라세벡 결핵 임상 2A상 최종결과 논문 발표…”글로벌 학계 주목”
2025-03-26	큐리언트 텔라세벡, WHO 글로벌 회의에서 임상 중간결과 발표…”허가 가시화”
2025-03-14	큐리언트, 동구바이오제약으로부터 80억 원 규모 유상증자 결정…1년 내 세 번째 투자

Company

Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More
Business philosophy

Innovation for unmet medical needs

Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More
Pipeline

Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More
IR/PR

Dear Qurient shareholders

Qurient would like to share brief updates on current progress made on its portfolio programs. See More